Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-04-13

Clinical Trial Update: A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tenapanor for constipation-predominant irritable bowel syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tenapanor (tenapanor)

Snippet

Sponsor: Ardelyx | Conditions: Constipation Predominant Irritable Bowel Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2020-04-13